Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

NCT01164475 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Granulocyte-colony stimulating factor (G-CSF)
DRUG: Fixed Dose Plerixafor
DRUG: Weight-Based Plerixafor

Sponsor

Genzyme, a Sanofi Company